Frontiers in endocrinology · 2026
Development and validation of a prediction model for psychological distress in patients with differentiated thyroid cancer undergoing ¹³¹I therapy.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeng Lingling, Ma Yiming, Yang Suyun
Аннотация
OBJECTIVE: To develop and validate a risk prediction model for psychological distress in patients with differentiated thyroid cancer (DTC) undergoing ¹³¹I therapy.
METHODS: A total of 247 DTC patients who received ¹³¹I therapy at a tertiary Grade A hospital in Taiyuan between May and December 2025 were enrolled. Independent risk factors for psychological distress were identified to construct the model. Model performance was evaluated using receiver operating characteristic (ROC) curves, the Hosmer-Lemeshow test, and calibration curves.
RESULTS: Multivariate logistic regression identified poor sleep quality, thyroid-stimulating hormone (TSH) stimulation, pulmonary metastasis, social support, radiation exposure concerns, and lower serum 25-hydroxyvitamin D levels as independent risk factors (all P < 0.05). The nomogram model achieved an area under the ROC curve (AUC) of 0.835, with a sensitivity of 83.1% and a specificity of 68.2%. The Hosmer-Lemeshow test yielded a χ² of 12.064 (P = 0.148). Calibration curves and decision curve analysis (DCA) confirmed good calibration and clinical utility. Internal validation via bootstrap resampling and 10-fold cross-validation produced AUCs of 0.82 and 0.77, respectively.
CONCLUSION: This internally validated model is a promising tool for predicting psychological distress in DTC patients undergoing ¹³¹I therapy. However, external validation in larger, multicenter cohorts is necessary before routine clinical use can be recommended.
METHODS: A total of 247 DTC patients who received ¹³¹I therapy at a tertiary Grade A hospital in Taiyuan between May and December 2025 were enrolled. Independent risk factors for psychological distress were identified to construct the model. Model performance was evaluated using receiver operating characteristic (ROC) curves, the Hosmer-Lemeshow test, and calibration curves.
RESULTS: Multivariate logistic regression identified poor sleep quality, thyroid-stimulating hormone (TSH) stimulation, pulmonary metastasis, social support, radiation exposure concerns, and lower serum 25-hydroxyvitamin D levels as independent risk factors (all P < 0.05). The nomogram model achieved an area under the ROC curve (AUC) of 0.835, with a sensitivity of 83.1% and a specificity of 68.2%. The Hosmer-Lemeshow test yielded a χ² of 12.064 (P = 0.148). Calibration curves and decision curve analysis (DCA) confirmed good calibration and clinical utility. Internal validation via bootstrap resampling and 10-fold cross-validation produced AUCs of 0.82 and 0.77, respectively.
CONCLUSION: This internally validated model is a promising tool for predicting psychological distress in DTC patients undergoing ¹³¹I therapy. However, external validation in larger, multicenter cohorts is necessary before routine clinical use can be recommended.